<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504712</url>
  </required_header>
  <id_info>
    <org_study_id>300</org_study_id>
    <nct_id>NCT00504712</nct_id>
  </id_info>
  <brief_title>Testosterone for Peripheral Vascular Disease</brief_title>
  <official_title>A Randomised, Double Blind, Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barnsley Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barnsley Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is increasing evidence of the linkage of type 2 diabetes with low testosterone levels
      in men. Testosterone treatment has shown beneficial effects on blood sugar control and
      obesity in pilot studies in men with type 2 diabetes. Beneficial effects have also been seen
      on angina- a disease related to atherosclerosis (narrowing of the arterial blood vessels).
      Peripheral vascular disease is also caused by atherosclerosis. We hypothesise that
      testosterone will have beneficial effects on peripheral vascualr disease in men with low
      serum testosterone and type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2006</start_date>
  <completion_date type="Anticipated">February 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in arterial stiffness</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in IMT</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in transcutaneous oxygen level</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ABPI</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Walking Impairment Questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>ACTIVE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone 200 mg intramuscular every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Sustanon- 200mg- Intramuscular testosterone every 2 weeks</description>
    <arm_group_label>ACTIVE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% saline</intervention_name>
    <description>Saline injection every two weeks</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes mellitus.

          2. Serum testosterone 12 nmol/L or less on two consecutive samples taken on different
             days and symptoms compatible with hypogonadism.

          3. Peripheral vascular disease as defined by

               -  previous diagnosis by a specialist vascular surgeon OR

               -  ABPI less than 0.92 and ischaemic leg pain (claudication or rest pain) or distal
                  complications (non-healing arterial foot ulcer or gangrene).

          4. Agreement to maintain antihypertensive and antilipid treatments at prior doses during
             3 month duration of study.

          5. Ability to give written informed consent after verbal and written explanation in the
             English language.

          6. Ability to comply with all study requirements.

        Exclusion Criteria:

          1. Current or previous breast cancer.

          2. Current or previous prostate cancer.

          3. Raised prostate specific antigen (PSA) or abnormal per rectal examination unless
             prostate cancer excluded after specialist urology opinion.

          4. Severe symptoms of benign prostatic hypertrophy (‘prostatism’)

          5. Treatment with testosterone in the 3 months prior to the trial.

          6. Investigational drug treatment in the 3 months prior to the trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T Hugh Jones</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barnsley Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roger D Stanworth</last_name>
    <phone>01226 777947</phone>
    <email>roger.stanworth@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barnsley Hospital NHS Foundation Trust</name>
      <address>
        <city>Barnsley</city>
        <state>South Yorkshire</state>
        <zip>S75 2EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger D Stanworth</last_name>
      <phone>01226 777947</phone>
      <email>roger.stanworth@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <last_update_submitted>July 19, 2007</last_update_submitted>
  <last_update_submitted_qc>July 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2007</last_update_posted>
  <keyword>Testosterone</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Diabetes</keyword>
  <keyword>PVD</keyword>
  <keyword>RCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

